Myriad Genetics’ Post

At Myriad, we believe that all patients should have access to an accurate picture of their breast cancer risk, which is why we validated our breast cancer risk assessment tool MyRisk with RiskScore in 2021 for women of all ancestries. Working with industry leading researchers, we assessed data from more than 275,000 women to validate our enhanced method for assessing polygenic breast cancer risk assessments in women across ancestries. Myriad’s providers have already seen impact that polygenic risk scores can have in helping identify breast cancer earlier; we’re pleased to see more data from others that also say the same. It’s important to support research that helps to address ethnic #disparities in #healthcare to protect #healthequity for all.

Although breast cancer rates among Black women and white women are similar, Black women face a 41% higher mortality rate. "Racial disparities are a bitter reality of many aspects of cancer care, but these discrepancies are most acute in breast cancer, as the leading cause of cancer death in Black women," STAT describes. Discover how using a different genomic evaluation for Black women, which examines 150 genes within a tumor, compared to 21 genes through a conventional test, could provide a more comprehensive understanding, "giving every patient an accurate risk evaluation, more appropriate and personalized treatment choices, and better outcomes":https://bit.ly/3Rwt0ks #HealthEquity #CancerResearch #Immunotherapy #CancerDisparities

"Breaking barriers in breast cancer research: Twelve new genes associated with breast cancer risk have been uncovered, particularly significant for women of African descent. This breakthrough not only enhances our understanding of the disease but also has the potential to revolutionize risk assessment and personalized treatment strategies. Let's celebrate diversity in medical research and continue striving for equitable healthcare outcomes for all. #BreastCancerResearch #DiversityInScience"

Did you know that a family history of pancreatic, ovarian, or prostate cancer can put you in a genetic predisposition for breast cancer? OHC advanced practice provider Sarah Mancini explains the connection. “Women who have the BRCA1 or BRCA2 genes, the genes typically associated with breast cancer, may also have genetic mutations associated with ovarian, prostate, and pancreatic cancers. This is why knowing your family cancer history is incredibly important. If your family history includes these 3 cancers, there is a chance you could be genetically predisposed to be diagnosed with breast cancer. A lot of women believe that if they don’t have breast cancer in their family history, they are safe, but unfortunately, that isn’t always the case. “Know your paternal and maternal family history and share that with your healthcare provider. Being proactive can help you focus on risk reduction, even if you have the genes associated with breast cancer.” The OHC cancer genetics team can help determine if you’re eligible for genetic testing. You don’t need to be an OHC patient to schedule an appointment. Call 888-649-4800 or visit ohcare.com. #pancreaticcancer #prostatecancer #ovariancancer #breastcancer #breastcancerawarenessmonth

This article reinforces one of the reasons I joined Geno.Me. With genetic testing more affordable, empowering more people to leverage their data to protect their health and to contribute to medical research, putting our Contributors in control of how that data is used in research is very motivating!

July is Sarcoma and Bone Cancer Awareness Month Join us in recognizing Sarcoma and Bone Cancer Awareness Month, highlighting the importance of research and advancements in these rare cancers. Sarcomas form in bones or soft tissues like cartilage, fat, muscle, and nerves. Bone cancers, such as osteosarcoma and Ewing sarcoma, primarily affect children and adolescents, while soft tissue sarcomas are more common in older adults. In 2024, an estimated 13,590 cases of soft tissue sarcoma and 3,970 cases of bone and joint cancer will be diagnosed in the U.S. Despite being challenging to diagnose early, advancements in treatment have improved survival rates. The five-year survival rate for soft tissue sarcomas is now 65.9%, and for bone and joint sarcomas, it is 68.2%. Significant progress has been made in research, with immunotherapy and gene expression targeting showing promise. Continued support and advancements in research are crucial to finding better ways to prevent and treat these cancers. #SarcomaAwareness #BoneCancerAwareness #CancerResearch

My authored article for the breast cancer awareness month, published in ETHealthWorld on the changing paradigm of breast cancer highlighting the causes, advances in testing including role of companion diagnostics, genomics & AI and the future steps to address this globally rising menace, with special attention on the Indian scenario, where the disease tends to affect younger population and is more aggressive. https://lnkd.in/d2UstG5F Agilus Diagnostics Fortis Healthcare #breastcancerawarenessmonth #moleculardisease #diagnosis #testing #genetics #AI #recurrencerisk #hormonereceptorpositivebreastcancer #triplenegativebreastcancer #companiondiagnistics #Indianscenario #nooneshouldfacebreastcanceralone

Black women tend to have more aggressive types of breast cancer and, despite advances in treatment, still face a higher death rate than white women. Adding to the existing disparities in diagnosis and treatment, it has recently been reported that a popular 21-gene breast cancer genomic test is less accurate in Black women, resulting in the misclassification of some patients as low/intermediate risk when further testing with a more comprehensive genomic test showed they are actually high risk. This impacts the ability to optimize treatment strategies, and has led to many black women being undertreated for their disease. This article in STAT highlights the existing racial disparities, underscoring the need for better representation in clinical trials and for oncologists to choose the best molecular testing for each individual patient. #BreastCancer #Diagnostics #PrecisionMedicine #Genomics

Did you know that 1 in 8 women will be diagnosed with breast cancer in their lifetime? While the United States Preventive Services Task Force (USPSTF) has developed specific screening recommendations to help detect early-stage cancer, those guidelines are aimed at all women regardless of risk. Noticing that a gap exists in providing tailored recommendations for those at lower risk, experts are beginning to understand how genetics can play a role in breast cancer screenings.    Physicians and scientists from the Healthy Nevada Project, the largest community-based population health study in Nevada, and the population genetic company Helix, conducted an analysis of 25,591 women and classified 9.1% as having a low genetic risk for breast cancer. It is suggested that delayed mammogram screenings may be beneficial for women at this lower risk level.     Recently published in the JAMA, Journal of the American Medical Association, this research seeks to emphasize the value of genetics in individualizing breast screening guidelines for patients at low risk for breast cancer. Learn more about the proposed screening recommendations: https://bit.ly/3vqdu0f  

Join us this February 28 for a #CancerGenomicsCloud webinar on genomic rearrangements in cancer!  Isabel Rodriguez & Ayse Keskus from the National Cancer Institute (NCI) will present groundbreaking research on #HPV infections in #cervicalcancer & head and neck cancers. Discover how they're cracking cancer's code and revealing key breakage-fusion-breakage events using long-read DNA sequencing data. Don't miss out! 🔍💡 Register at: https://lnkd.in/ekRRugui or ping me if you have any questions! #bioinformatics #CRDC #cancerresearch